Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor
- Ming Chu†1Email author,
- Ran Ding†2,
- Zheng-yun Chu2,
- Ming-bo Zhang2,
- Xiao-yan Liu1,
- Shao-hua Xie1,
- Yan-jun Zhai2 and
- Yue-dan Wang1Email author
© Chu et al.; licensee BioMed Central Ltd. 2014
Received: 18 August 2013
Accepted: 18 February 2014
Published: 6 March 2014
Berberine is an isoquinoline alkaloid mainly extracted from Rhizoma Coptidis and has been shown to possess a potent inhibitory activity against bacterial. However, the role of berberine in anti-bacterial action has not been extensively studied.
The animal model was established to investigate the effects of berberine on bacterial and LPS infection. Docking analysis, Molecular dynamics simulations and Real-time RT-PCR analysis was adopted to investigate the molecular mechanism.
Treatment with 40 mg/kg berberine significantly increased the survival rate of mice challenged with Salmonella typhimurium (LT2), but berberine show no effects in bacteriostasis. Further study indicated that treatment with 0.20 g/kg berberine markedly increased the survival rate of mice challenged with 2 EU/ml bacterial endotoxin (LPS) and postpone the death time of the dead mice. Moreover, pretreatment with 0.05 g/kg berberine significantly lower the increasing temperature of rabbits challenged with LPS. The studies of molecular mechanism demonstrated that Berberine was able to bind to the TLR4/MD-2 receptor, and presented higher affinity in comparison with LPS. Furthermore, berberine could significantly suppressed the increasing expression of NF-κB, IL-6, TNFα, and IFNβ in the RAW264.7 challenged with LPS.
Berberine can act as a LPS antagonist and block the LPS/TLR4 signaling from the sourse, resulting in the anti-bacterial action.
Berberine is an isoquinoline alkaloid extracted from variety species of plants such as Rhizoma Coptidis. It has been widely used for treatment of skin inflammation, diabetes, liver disease [2–4]. More importantly, berberine has been used in the treatment of enteritis [5, 6] for thousands of years in China, and presents the advantages of shorter treatment course, faster currative effect, little side effect, and milder tolerance. However, the role of berberine in antibacterial action has not been extensively studied. Since the process of bacterial infection and the pathogenic mechanisms of bacterial are complicated, it is hard to define the role of berberine in anti-bacterial action without an in-depth study. Enteritis is most commonly caused by the ingestion of substances contaminated with pathogenic microorganisms, such as Salmonella and Escherichia . The symtoms of enteritis include abdominal pain, cramping, dehydration, diarrhea and fever, which are mainly caused by the bacterial endotoxin infection.
Endotoxin is considered to be a toxin kept “within” the bacterial cell and to be released only after destruction of the bacterial cell wall. Nowadays, endotoxin is used synonymously with the term LPS, which is a major constituent of the outer cell membrane of Gram-negative bacteria [8, 9]. The key effects of LPS on vertebrates are mediated by their interaction with specific receptors on immune cells such as monocytes, macrophages, dendric cells, and others. LPS consists of a hydrophobic anchor, known as lipid A, a repeating O-antigen polysaccharide, and an inner core oligosaccharide [10, 11]. Many of the immune activating abilities of LPS can be attributed to the lipid A unit, which binds to the toll-like receptor 4 (TLR4), and activates the host defence effector system by rapidly triggering pro-inflammatory processes [12–15]. TLR4 alone does not directly bind LPS and requires its coreceptor myeloid differentiation protein (MD-2) which is associated with the extracellular domain of TLR4 and is indispensable for LPS recognition since MD-2 has a unique hydrophobic cavity which can directly bind the lipid A unit [16, 17]. The combination between LPS and TLR4/MD-2 receptor complex can cause intense innate immune response [18–20]. After binding LPS, TLR4 undergoes oligomerization and recruits its downstream adaptors via interactions with the TIR (Toll-interleukin-1 receptor) domains. MyD88 (myeloid differentiation primaryresponse gene 88) is one of the five TIR domain-containing adaptor proteins. The TLR4 signaling has been divided into MyD88-dependent and TRIF-dependent path-way. MyD88 activates the downstream transcription factors AP-1, IRF-5 and NF-κB. These transcription factors induce expression of proinflammatory cytokine genes, and thus a series of proinflammatory cytokines (TNF-α, IFN-γ, IL-1, IL-6) are produced through the MyD88-dependent pathway [13, 21, 22]. Currently, LPS is the most important factor in induction of IL-1 and TNF . These cytokines can regulate the immune responses via the activation of various transcription factors within the fever-controlling region of the hypothalamus to increase the body temperature . Meanwhile, inflammatory reactions induced by LPS can also cause diarrhea . Furthermore, according to the recent evidences, TLR4-mediated elevations in the expression of these cytokines in astrocytes in the central nervous system (CNS) and glia cells can initiate and propagate several debilitating disease states such as sepsis and chronic pain [26–29]. One study demonstrated that berberine inhibits LPS-stimulated myocardial TNF-alpha production, impairs calcium cycling, and improves LPS-induced contractile dysfunction in intact heart within cardiomyocytes exposed to LPS adopted . Another study which adopted LPS-stimulated macrophages demonstrated that berberine could inhibit COX-II activity . Other studies have indicated that Berberine could attenuate tissue injury of the lungs and intestine in mice challenged with LPS and could suppress the activation of NF-κB [32–35]. The above mentioned studies seem to indicate that berberine may block LPS signaling and have some preventitive effects on LPS-induced injury. However, previous research did not clearly identify the stage at which berberine blocks the LPS inflammatory signal.
The crystal structure of human TLR4/MD-2/Ra-LPS complex  has been reported and may interact with berberine since it has a large hydrophobic surface, which is likely to compete with LPS in binding to its specific TLR4/MD-2 receptor, thus blocking the LPS/TLR4 signaling. Based on the previous in vitro and animal work, and on our hypothesis that berberine may block the LPS signaling by binding to the TLR4/MD-2 receptor, berberine may present alleviative effects on LPS-induced disease states. In the present study, we first confirmed the anti-bacterial effect. Afterward, we investigated the therapeutic effects of berberine on LPS-induced diseases, thereby providing the evidence supporting the need for the study of anti-endotoxin mechanism. Furthermore, we explored the molecular mechanisms of the action of berberine.
Berberine was provided by Liaoning University of Traditional Chinese Medicine. Endotoxin was provided by National Institutes for Food and Drug Control. (titer: 9000 EU/amp).
Wild type S.typhimurium LT2 was purchased from ATCC (Catalog number: 15277). LT2 was grown in Luria-Bertani (LB) medium at 37°C with shaking at 200 rpm. When appropriate, the medium was supplemented with 10 μg of tetracycline per ml medium or 10 μg of chloramphenicol.
Cell culture and treatment
Murine macrophage-like cells (RAW264.7) were purchased from ATCC and cultured in Dulbecco’s modified Eagle’s medium (Mediatech Inc., Herndon, VA, USA) supplemented with 100 μg/ml of penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (Gibco, FBS), in a humidified atmosphere of 5% CO2 at 37°C, until reaching 80% confluency. The medium was changed every 3 days. These cells were divided into four treatment groups.
Animals and experimental procedures
Balb/c mice(4-6 weeks, weighing 21-23 g)and albino rabbits(weighing 1.5-2.5 kg) were provided by animals’ raising house of Shenyang Medical College (Certificate of Conformity: Liao  No. 022). The experimental animals were housed separately at room temperature (20 ± 2)°C, humidity 55%-60%. They were provided a standard laboratory diet and water ad libitum. Before the experiments, we measured the body temperature of the rabbits twice a day for three consecutive days. The rabbits which temperature range from 38.6°C to 39.5°C, and which temperature fluctuation range less than 0.3°C were selected. All of the experimental procedures were carried out in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals. The animal experiments were approved by the Institutional Animal Care and Use Committee of the Peking University.
The establishment of LT2-infected Balb/c mice model—All the Balb/C mice challenged via the oral administration with 7.6 × 105 CFU LT2 by blunt-tipped gauge needle were divided into five groups. Each mice in berberine group was inoculated orally with 0.5 ml LB broth in the presence of berberine with different final concentrations (10, 20, 30, 40 mg/kg) for 7 consecutive day. While the mice in non-treatment group inoculated orally with 0.5 ml LB broth for consecutive 7 days was set as control. The survival of mice in each group was assessed once a day for 8 consecutive days.
The establishment of LPS-treated Balb/c mice model—Each Balb/c mouse was injected intraperitoneally with 2EU/ml bacterial endotoxin(0.5 ml for each mouse). The mice in berberine group were administered intragastrically with berberine solution at the dose of 0.20, 0.16 or 0.13 g/kg, in comparison with the non-treatment mice which were administered intragastrically with distilled water (0.01 ml/g). The survival of mice in each group was assessed once an hour throughout the experiment.
The establishment of LPS-treated pyretic rabbits model—Before the oral administration, the rectal temperature was measured once an hour for 2 hours, and the average value was set as the basal body temperature. The rabbits in berberine group were administered intragastrically with berberine solution at the doses of 0.06, 0.05 or 0.04 g/kg, in comparision with the non-treament rabbits. One hour after the administration, the rabbits were injected with 0.8 EU/kg bacterial endotoxin through their ear vein. Lastly, the body temperature was measured once an hour for five consecutive hour and the changes in body temperature (the difference between the body temperature and basal body temperature pyrogenic Δ T °C) were calculated.
Docking studies with autodock 4.2
The crystal structure of human MD-2 complexed with lipid IVa (2E59. pdb)  was used for docking studies with Autodock v4.2. The protein was processed by removing the native ligand and addition of polar hydrogen atom and Kollman united-atom partial charges. The berberine was prepared by assigning Gasteiger–Marsilli atomic charge and defining active torsion groups. Grid maps were calculated with 40 × 86 × 54 points spacing by 0.375 Å, centered at point (0.445, 23.87, 13.078) using Autogrid4. The docking studies were carried out with flexible ligand using Lamarckian Genetic Algorithm with the following parameters: translation step (2 Å), quaternion step (50°), torsional step (50°), torsinal degree of freedom (2). All other parameters were set to their default values. The protein and ligand berberine were further prepared with AutodockTools . The analysis of the docking was performed with AutoDockTools, and PyMOL software .
Molecular dynamics simulations
Molecular dynamics (MD) simulations were carried out with Gromacs v4.5 program [40, 41]. The structure of protein was taken from the Protein Data Bank (2E59.pdb). Gromos96 (53a) force field was used for the protein, and the parameters for the berberine are generated with PRODRG web server [42, 43]. The protein was solvated with a rectangular water box extending 10 Å from the protein. Single Point Charge (SPC) model was used for the waters. Four berberine moleculars were randomly placed around the protein within 2 Å. Two Cl- ions were added to neutralize the total charge of system.
In preparation for MD, the system was first subjected to 1000 steps of steepest descent minimization. Then the system was heated to the 298 K with the protein partially constrained. Finally 85 ns MD simulation for equilibration and production was carried out for the system with 3D periodic boundary in NPT ensemble imposed. Weak coupling methods  were applied with coupling constants of 0.1 ps and 0.5 ps respectively to maintain the systems at 298 K and 1 Bar. Bonds involving hydrogen were constained with LINCS algorithm for protein and SETTLE algorithm for water [45, 46], thus permitted using a integrate step of 2 fs. Electrostatic interactions were treated by utilizing Particle Mesh Ewald (PME) method [47, 48] beyond the cutoff at 10 Å. Van der Waals interactions were cut off at distance of 14 Å. Neighbor lists were used with a list cutoff of 10 Å and update frequency of every 10 steps. Snapshots of trajectories were saved every 10 picoseconds for analysis.
Real-time RT-PCR analysis of NF-κB, IL-6, TNFα, and IFNβ mRNA expression
Total RNA was recovered from RAW264.7 cells using the Trizol reagent (Invitrogen) and Dnase treated using Turbo Dnase® (Ambion). RNA was reverse transcribed using the Superscript™ first-strand cDNA synthesis kit (Invitrogen). Primer sequences for mouse NF-κB were 5′-CAG CCA GGA TTG AGG ATA TGA G-3′ and 5′-TTC GGA CAA CAG AAG TCA GGA G-3′; for IL-6 were 5′-AAC GAT GAT GCA CTT GCA GA-3′ and 5′-GAG CAT TGG AAA TTG GGG TA-3′; for TNFα were 5′-TCC CCA AAG GGA TGA GAA GTT C-3′ and 5′-TCA TAC CAG GGT TTG AGC TCA G-3′; for IFNβ were 5′-CCA CAG CCC TCT CCA TCA AC-3′ and 5′-CTA CCA CCA GGC TCG TCT CT-3′; for β-actin were 5′-ATG GGT CAG AAG GAC TCC TAC G-3′ and 5′-AGT GGT ACG ACC AGA GGC ATA C-3′, for the sense and antisense primers, repectively. Thermal cycling conditions for the PCR reactions were 94°C for 5 min followed by 40 cycles of 94°C for 45 s, 61°C for 30 s, and 72°C for 30 s. Polymerase reaction products amplified by these primers were cloned into pGEMT vector (Promega) and sequenced for verification. Real-time reactions were carried out on a real-time machine (Biorad) using the IQ™ SYBR® Green Supermix kit (Biorad). The abundance of each gene product was calculated by regressing against the standard curve generated in the same reaction with their respective plasmids. The NF-κB, IL-6, TNFα, and IFNβ values for each sample were normalized to β-actin.
Statistic analyses were performed by using SPSS 13.0 software. The data are expressed as mean ± SD. Student’s T test was used in the data statistics. Values of P < 0.05 were considered significant.
Anti-bacterial effects of berberine
Effects of berberine on the survival from LPS induced death of BalB/C mouse
Effects of berberine on the LPS induced fever of pyretic rabbit
Role of berberine in the combination between LPS and its receptor molecules
Role of berberine in LPS induced expression of NF-κB and cytokines
Berberine has been used in the treatment of enteritis [5, 6] for thousands of years in China, and presents the advantages of shorter treatment course, faster currative effect, little side effect and milder tolerance. However, the mechanism of berberine in anti-bacterial is still unclear.
In this study, we showed that berberine had no effect on bacteriostasis. As known, LPS plays an important role in bacterial infection. Therefore, we assumed that the anti-bacterial effects of berberine might be related to its inhibitory action on LPS infection. As we expected, The results indicated that berberine could reduce the lethal rate of mice infected by LPS, and extend the survival time. Subsequently, we demonstrated that berberine could significantly relieve fever of rabbits induced by LPS. Based on these, we believe that there must exsits some definite link between berberine and LPS signaling.
The real-time pcr analysis demonstrated that berberine can reduce the mRNA expression of NF-κB, IL-6, TNFα and IFNβ in LPS-challenged RAW264.7. Other studies have indicated that LPS significantly induced enterocyte apoptosis, increased TLR4 mRNA expression, MIP-2 production, I-κBα phosphorylation, and myeloperoxidase content in the ileum and pretreatment of berberine alleviated all the alterations . Beside these, another study showed that berberine can suppress the activation of TLR4 and NF-κB in the ileum of mice . Those mentioned studies seem to verify that berberine can block the LPS/TLR4 signaling pathway. But former studies have not revealed how berberine block the signaling.
Since the binding of Lipid A and the hydrophobic cavity of MD-2 play an key role in LPS recognition, and a berberine molecule has a large hydrophobic surface, we hypothesized that berberine would be likely to compete to bind TLR4/MD-2, thereby blocking the signaling. We first adopt docking calculation to investigate whether the berberine molecules can bind to the MD2. The results indicated that berberine could bind to free MD-2 with binding free energy of -7.70 kcal/mol. The binding cavity of MD-2 is large enough that it would still have sufficient empty space although a molecule of berberine have already bound to it. Afterward, the other berberine molecules was docked continually into MD-2. As a result, the cavity of MD-2 could hold two more berberine molecules with the binding energies of -7.33 and -6.75 kcal/mol respectively. Therefore, a MD-2 receptor with an open cavity could accept at least three berberine molecules. Furthermore, to investigate whether berberine could bind to MD-2 under the influence of water solvent, a MD simulation of a system with four molecules of berberine randomly distributed around MD-2 was carried out. The presence of water solvent squeezed MD-2 so strongly that the hydrophobic cavity of the MD-2 was collapsed. However, one of the four molecules of berberine was still observed to enter the cavity of MD-2 after 85 ns of MD simulation. Meanwhile, another molecule of berberine approached to the enrance to the cavity. It can be expected that this molecule might also enter the pocket if a longer simulation was performed.
TLR4 has therefore been recognized as an important pharmacological target. In addition to being responsible for fever and diarrhea, the TLR4 activation caused by endotoxin with subsequent cytokine production can lead to life-threatening syndromes such as sepsis and septic shock. Mortality of patients who has suffered from septic shock is still 40%–60% despite rapid progress in developing antibiotics and other therapeutic methods in clinical practice . Some drugs were designed and synthesized to interrupt LPS from binding to TLR4/MD2 receptor complex, such as Eritoran, Taxol and some protein drugs. With the advantage of lower cost, faster currative effect, and little side effect, berberine, the newly-discovered LPS antagonist, could be widely utilized as a substitute for expensive drugs in the treatment of LPS-induced diseases.
Furthermore, in recent years, the phenomenon of the over prescription ofantibiotics have led to increased bacterial resistance to antibiotics. Berberine are expected to be such a kind of drug which can be widely used in the clinical treatment of wide range of diseases instead of antibiotics in order to decrease the over use of antibiotics which have led to progression of increased bacterial antibiotic resistance.. Based on this, it is essential to figure out the antibacterial mechanism of berberine in order to provide a theoretical basis for the further application of berberine in the treatment of diseases caused by the infection of bacteria and the endotoxin (LPS) released by bacteria. Since the process of bacterial infection is complicated, there might exist other possible antibacterial mechanisms of berberine which we will further investigate. We believe that further study on berberine will aid in our ability to design effective interventions and treatments for bacterial infection diseases.
Berberine can act as a LPS antagonist and block the LPS/TLR4 signaling from the sourse, resulting in the anti-bacterial action.
ΔProject 81172884 was supported by National Natural Science Foundation of China; ΔProject J1030831/J0108 supported by the Fund for Fostering Talents in Basic Science of the National Natural Science Foundation of China.
- Asai M, Iwata N, Yoshikawa A, Aizaki Y, Ishiura S, Saido TC, Maruyama K: Berberine alters the processing of Alzheimer’s amyloid precursor protein to decrease Abeta secretion. Biochem Biophys Res Commun. 2007, 352: 498-502. 10.1016/j.bbrc.2006.11.043.View ArticlePubMed
- Mantena SK, Sharma SD, Katiyar SK: Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006, 5: 296-308. 10.1158/1535-7163.MCT-05-0448.View ArticlePubMed
- Kuo CL, Chi CW, Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004, 203: 127-137. 10.1016/j.canlet.2003.09.002.View ArticlePubMed
- Hui Dong NW, Li Z, Fuer L: Berberine in the treatment of type2 diabetesmellitus: a systemic review and meta-analysis. Evid based complement. Alternat Med. 2012, 2012: 591654-
- Lin Y, Zhou Z, Shen W, Shen J, Hu M, Zhang F, Hu P, Xu M, Huang S, Zheng Y: Clinical and experimental studies on shallow needling technique for treating childhood diarrhea. J Tradit Chin Med. 1993, 13: 107-114.PubMed
- Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K: Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis. 1987, 155: 979-984. 10.1093/infdis/155.5.979.View ArticlePubMed
- Thomas L: The physiological disturbances produced by endotoxins. Annu Rev Physiol. 1954, 16: 467-490. 10.1146/annurev.ph.16.030154.002343.View ArticlePubMed
- Leonardo MR, Silva RA, Assed S, Nelson-Filho P: Importance of bacterial endotoxin (LPS) in endodontics. J Appl Oral Sci. 2004, 12: 93-98.PubMed
- Panda SK, Kumar S, Tupperwar NC, Vaidya T, George A, Rath S, Bal V, Ravindran B: Chitohexaose activates macrophages by alternate pathway through TLR4 and blocks endotoxemia. PLoS Pathog. 2012, 8: e1002717-10.1371/journal.ppat.1002717.PubMed CentralView ArticlePubMed
- Gattis SG, Chung HS, Trent MS, Raetz CR: The Origin of 8-Amino-3, 8-dideoxy-D-manno-octulosonic Acid (Kdo8N) in the Lipopolysaccharide of Shewanella oneidensis. J Biol Chem. 2013, 288: 9216-9225. 10.1074/jbc.M113.453324.PubMed CentralView ArticlePubMed
- Herath TD, Darveau RP, Seneviratne CJ, Wang CY, Wang Y, Jin L: Tetra- and penta-acylated lipid a structures of porphyromonas gingivalis LPS differentially activate TLR4-mediated NF-κB signal transduction cascade and immuno-inflammatory response in human gingival fibroblasts. PLoS One. 2013, 8: e58496-10.1371/journal.pone.0058496.PubMed CentralView ArticlePubMed
- Ohto U, Fukase K, Miyake K, Shimizu T: Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/ MD-2. Proc Natl Acad Sci USA. 2012, 109: 7421-7426. 10.1073/pnas.1201193109.PubMed CentralView ArticlePubMed
- Peri F, Piazza M, Calabrese V, Damore G, Cighetti R: Exploring the LPS/TLR4 signal pathway with small molecules. Biochem Soc Trans. 2010, 38: 1390-1395. 10.1042/BST0381390.View ArticlePubMed
- Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K: Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol. 2006, 24: 353-389. 10.1146/annurev.immunol.24.021605.090552.View ArticlePubMed
- Beutler B: TLR4 as the mammalian endotoxin sensor. Curr Top Microbiol Immunol. 2002, 270: 109-120.PubMed
- Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999, 189: 1777-1782. 10.1084/jem.189.11.1777.PubMed CentralView ArticlePubMed
- Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K: Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002, 3: 667-672.PubMed
- Beutler B, Rietschel ET: Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol. 2003, 3: 169-176. 10.1038/nri1004.View ArticlePubMed
- Lacatus M: Innate immunity in surgical patients. Chirurgia (Bucur). 2013, 108: 18-25.
- Salomao R, Brunialti MK, Rapozo MM, Baggio-Zappia GL, Galanos C, Freudenberg M: Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock. 2012, 38: 227-242. 10.1097/SHK.0b013e318262c4b0.View ArticlePubMed
- Watanabe S, Kumazawa Y, Liposomal IJ: Lipopolysaccharide initiates TRIF-dependent signaling pathway independent of CD14. PLoS One. 2013, 8: e60078-10.1371/journal.pone.0060078.PubMed CentralView ArticlePubMed
- Vandenbon A, Teraguchi S, Akira S, Takeda K, Standley DM: Systems biology approaches to toll-like receptor signaling. Wiley Interdiscip Rev Syst Biol Med. 2012, 4: 497-507. 10.1002/wsbm.1178.PubMed CentralView ArticlePubMed
- Schindler R, Gelfand JA, Dinarello CA: Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood. 1990, 76: 1631-1638.PubMed
- Gautron L, Lafon P, Chaigniau M: Tramu G, and Laye S (2002) Spatiotemporal analysis of signal transducer and activator of transcription 3 activation in rat brain astrocytes and pituitary following peripheral immune challenge. Neuroscience. 2002, 112: 717-729. 10.1016/S0306-4522(02)00115-X.View ArticlePubMed
- Liang YC, Liu HJ, Chen SH, Chen CC, Chou LS, Tsai LH: Effect of lipopolysaccharide on diarrhea and gastrointestinal transit in mice: roles of nitric oxide and prostaglandin E2. World J Gastroenterol. 2005, 11: 357-361.PubMed CentralView ArticlePubMed
- Slivka PF, Shridhar M, Lee GI, Sammond DW, Hutchinson MR, Martinko AJ, Buchanan MM, Sholar PW, Kearney JJ, Harrison JA, Watkins LR, Yin H: A peptide antagonist of the TLR4-MD2 interaction. Chembiochem. 2009, 10: 645-649. 10.1002/cbic.200800769.PubMed CentralView ArticlePubMed
- DeLeo JA, Tanga FY, Tawfik VL: Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist. 2004, 10: 40-52. 10.1177/1073858403259950.View ArticlePubMed
- Leon CG, Tory R, Jia J, Sivak O, Wasan KM: Discovery and development of toll-like receptor 4 (TLR4) antagonists:a new paradigm for treating sepsis and other diseases. Pharm Res. 2008, 25: 1751-1761. 10.1007/s11095-008-9571-x.PubMed CentralView ArticlePubMed
- Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, Rice KC, Watkins LR: Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008, 28: 20-29. 10.1111/j.1460-9568.2008.06321.x.PubMed CentralView ArticlePubMed
- Yang J, Wang HD, Lu DX, Wang YP, Qi RB, Li J, Li F, Li CJ: Effects of neutral sulfate berberine on LPS-induced cardiomyocyte TNF-alpha secretion, abnormal calcium cycling, and cardiac dysfunction in rats. Acta Pharmacol Sin. 2006, 27: 173-178. 10.1111/j.1745-7254.2006.00257.x.View ArticlePubMed
- Lee DU, Kang YJ, Park MK, Lee YS, Seo HG, Kim TS, Kim CH, Chang KC: Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF-alpha, iNOS, and IL-12 production in LPS-stimulated macrophages. Life Sci. 2003, 73: 1401-1412. 10.1016/S0024-3205(03)00435-1.View ArticlePubMed
- Li F, Wang HD, Lu DX, Wang YP, Qi RB, Fu YM, Li CJ: Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice. Acta Pharmacol Sin. 2006, 27: 1199-1205. 10.1111/j.1745-7254.2006.00368.x.View ArticlePubMed
- Gu L, Li N, Gong J, Li Q, Zhu W, Li J: Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis. 2011, 203: 1602-1612. 10.1093/infdis/jir147.View ArticlePubMed
- Li HM, Wang YY, Wang HD, Cao WJ, Yu XH, Lu DX, Qi RB, Hu CF, Yan YX: Berberine protects against lipopolysaccharide-induced intestinal injury in mice via alpha 2 adrenoceptor-independent mechanisms. Acta Pharmacol Sin. 2011, 32: 1364-1372. 10.1038/aps.2011.102.PubMed CentralView ArticlePubMed
- Zhang Q, Piao XL, Piao XS, Lu T, Wang D, Kim SW: Preventive effect of Coptis chinensis and berberine on intestinal injury in rats challenged with lipopolysaccharides. Food Chem Toxicol. 2011, 49: 61-69. 10.1016/j.fct.2010.09.032.View ArticlePubMed
- Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO: The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009, 458: 1191-1195. 10.1038/nature07830.View ArticlePubMed
- Ohto U, Fukase K, Miyake K, Satow Y: Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science. 2007, 316: 1632-1634. 10.1126/science.1139111.View ArticlePubMed
- Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ: AutoDock4 and Auto-DockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009, 30: 2785-2791. 10.1002/jcc.21256.PubMed CentralView ArticlePubMed
- Hammesfahr B, Odronitz F, Mühlhausen S, Waack S, Kollmar M: GenePainter: a fast tool for aligning gene structures of eukaryotic protein families, visualizing the alignments and mapping gene structures onto protein structures. BMC Bioinforma. 2013, 14: 77-10.1186/1471-2105-14-77.View Article
- Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ: Gromacs: fast, flexible, and free. J Comput Chem. 2005, 26: 1701-1718. 10.1002/jcc.20291.View ArticlePubMed
- Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D, Hess B, Lindahl E: GROMACS 4.5:a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013, 29: 845-854. 10.1093/bioinformatics/btt055.PubMed CentralView ArticlePubMed
- Schüttelkopf AW, van Aalten DMF: PRODRG-a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. 2004, D60: 1355-1363.
- Oostenbrink C, Villa A, Mark AE, van Gunsteren WF: A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem. 2004, 25: 1656-1676. 10.1002/jcc.20090.View ArticlePubMed
- Eslami H, Mojahedi F, Moghadasi J: Molecular dynamics simulation with weak coupling to heat and material baths. J Chem Phys. 2010, 133: 084105-10.1063/1.3474951.View ArticlePubMed
- Shen T, Wong CF, McCammon JA: Atomistic Brownian dynamics simulation of peptide phosphorylation. J Am Chem Soc. 2001, 123: 9107-9111. 10.1021/ja010190t.View ArticlePubMed
- Miyamoto S, Kollman PA: SETTLE: an analytical version of the SHAKE and RATTLE algorithms for rigid water models. J Comp Chem. 1992, 13: 952-962. 10.1002/jcc.540130805.View Article
- Lama D, Modi V, Sankararamakrishnan R: Behavior of solvent-exposed hydrophobic groove in the anti-apoptotic Bcl-XL protein: clues for its ability to bind diverse BH3 ligands from MD simulations. PLoS One. 2013, 8: e54397-10.1371/journal.pone.0054397.PubMed CentralView ArticlePubMed
- Isele-Holder RE, Mitchell W, Ismail AE: Development and application of a particle-particle particle-mesh Ewald method for dispersion interactions. J Chem Phys. 2012, 137: 174107-10.1063/1.4764089.View ArticlePubMed
- Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990, 249: 1431-1433. 10.1126/science.1698311.View ArticlePubMed
- Gioannini TL, Weiss JP: Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res. 2007, 39: 249-260. 10.1007/s12026-007-0069-0.View ArticlePubMed
- Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 2007, 19: 3-10. 10.1016/j.smim.2006.12.002.View ArticlePubMed
- Tobias PS, Soldau K, Ulevitch RJ: Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med. 1986, 164: 777-793. 10.1084/jem.164.3.777.View ArticlePubMed
- Wright SD, Tobias PS, Ulevitch RJ, Ramos RA: Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med. 1989, 170: 1231-1241. 10.1084/jem.170.4.1231.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/89/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.